1534-35-6 Usage
Description
(4R)-4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid is a complex organic compound with a unique molecular structure. It is characterized by its multiple stereocenters and functional groups, which contribute to its potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
(4R)-4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid is used as a pharmaceutical compound for its potential therapeutic properties. Its unique structure allows it to interact with specific biological targets, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, (4R)-4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid serves as a valuable compound for studying the effects of stereochemistry on biological activity. Its complex structure provides insights into the relationship between molecular configuration and function, which can be applied to the design of more effective drugs and other bioactive molecules.
Used in Drug Synthesis:
(4R)-4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid can be used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique functional groups and stereochemistry make it a versatile building block for the development of new drugs with improved efficacy and selectivity.
Note: The provided materials do not contain specific applications for (4R)-4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid. The uses listed above are inferred based on the compound's structural complexity and potential applications in related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1534-35-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,3 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1534-35:
(6*1)+(5*5)+(4*3)+(3*4)+(2*3)+(1*5)=66
66 % 10 = 6
So 1534-35-6 is a valid CAS Registry Number.
InChI:InChI=1/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17+,18+,19-,20+,21+,23+,24-/m1/s1
1534-35-6Relevant articles and documents
ISOLITHOCHOLIC ACID OR ISOALLOLITHOCHOLIC ACID AND DEUTERATED DERIVATIVES THEREOF FOR PREVENTING AND TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES
-
Page/Page column 17; 18, (2020/03/02)
The present invention relates to isolithocholic acid (3?-hydroxy-5?-cholan-24-oic acid, iso-LCA) and isoallolithocholic acid (3?-hydroxy-5α-cholan-24-oic acid) and their deuterated analogs for preventing or treating Clostridium difficile-associated disease in a mammalian subject.
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties
Incerti, Matteo,Russo, Simonetta,Corrado, Miriam,Giorgio, Carmine,Ballabeni, Vigilio,Chiodelli, Paola,Rusnati, Marco,Scalvini, Laura,Callegari, Donatella,Castelli, Riccardo,Vacondio, Federica,Ferlenghi, Francesca,Tognolini, Massimiliano,Lodola, Alessio
supporting information, (2020/01/29)
The EphA2 receptor has been validated in animal models as new target for treating tumors depending on angiogenesis and vasculogenic mimicry. In the present work, we extended our current knowledge on structure-activity relationship (SAR) data of two related classes of antagonists of the EphA2 receptor, namely 5β-cholan-24-oic acids and 5β-cholan-24-oyl L-β-homotryptophan conjugates, with the aim to develop new antiangiogenic compounds able to efficiently prevent the formation of blood vessels. As a result of our exploration, we identified UniPR505, N-[3α-(Ethylcarbamoyl)oxy-5β-cholan-24-oyl]-L-β-homo-tryptophan (compound 14), as a submicromolar antagonist of the EphA2 receptor capable to block EphA2 phosphorylation and to inhibit neovascularization in a chorioallantoic membrane (CAM) assay.
Triplet energy management between two signaling units through cooperative rigid scaffolds
Miro, Paula,Vayá, Ignacio,Sastre, Germán,Jiménez, M. Consuelo,Marin, M. Luisa,Miranda, Miguel A.
supporting information, p. 713 - 716 (2016/01/12)
Through-bond triplet exciplex formation in donor-acceptor systems linked through a rigid bile acid scaffold has been demonstrated on the basis of kinetic evidence upon population of the triplet acceptors (naphthalene, or biphenyl) by through-bond triplet-
